diethyl ether, they were placed on a warm pad maintained at 37°C and intubated and they underwent mechanical ventilation with a volume-cycled rodent ventilator (Model SN-480-7, Sinano Corporation, Tokyo, Japan) with a tidal volume of 0.9 ml room air and 1.5% isoflurane at the respiratory rate of 110-120 breaths/min. The chest cavity was opened in the second intercostal space at the left upper sternal border. The thymus was then gently removed to expose the aortic arch. After the transverse aorta was isolated between left and right carotid arteries, it was constricted by a 7-0 silk suture tied firmly against a 27-gauge needle. The latter was promptly removed to eventually yield a 65-70% constriction (outer diameter, 0.3 mm). 23 In the control group, the mice underwent similar surgical procedures without constriction of the aorta.
The mice were divided into 3 groups: TAC, candesartan (TAC plus chronic treatment with candesartan) and control groups. One day before operation, all the mice underwent an implantation of an osmotic mini-pump (Model 1002, Alza, Durect Corporation, Cupertino, CA, USA) in the subcutaneous space of the back. In a preliminary study, the relationship between candesartan dosage and blood pressure was examined using 2 different concentrations of candesartan (generously donated by Takeda Chemical Industries, Ltd, Japan) without the TAC operation in 27 mice for 4 weeks ( Table 1) . The blood pressure was measured in an unanaesthetized condition using the tail-cuff plethysmography method (Softron BP98-A, Softron corporation, Tokyo, Japan). 24 The dosage of 0.1 mg·kg -1 ·day -1 did not affect the systolic blood pressure. We therefore adopted this dosage for the whole experiment. In TAC and control group, the osmotic pump contained only saline, which was delivered at the same volume rate as in the candesartan group.
Echocardiography
The echocardiographic study was performed under anesthesia with spontaneous respiration before the operation, and 2 and 4 weeks after operation using intraperitoneal anesthesia with tribromoethanol/amylene hydrate (avertin) 2.5% w/v solution (8 l/g). 25 The echocardiographic data were obtained by an ultrasonographer, who was experienced in rodent imaging and unaware of the mice's treatment details, using a 15 MHz linear array transducer (Power Vision 8000, Toshiba Corporation, Japan). Briefly, after the anterior chest was shaved, the mice were placed on a warming pad. A standoff was used, with the depth set at 2 cm with the zoom mode to optimize resolution and penetration. Short-axis, 2 dimensional echocardiographic images were acquired at papillary levels. Short-axis Mmode images were obtained at a sweep speed of 100 mm/s from the same anatomic position. Three consecutive cardiac cycles were used for measurement. The thickness of the left ventricular (LV) anterior and posterior walls (LVAW and LVPW) was measured in end-systole and end-diastole.
Electrophysiological Studies
Mouse Preparation Four weeks after operation, the mice underwent EPS. They were again anesthetized with diethyl ether, intubated and mechanically ventilated with a volume-cycled rodent ventilator. The anesthesia procedure was the same as that for the TAC operation. A surface 6-lead electrocardiogram (ECG) was recorded in a supine position by subcutaneously placing 27-gauge needles in each limb. [23] [24] [25] [26] The midline cervical incision was made to expose the right external jugular vein, and an catheter (1.7F octapolar catheter with an interelectrode spacing of 0.5 mm, CIBer mouse EP, NuMed, Hopkinton, NY, USA) was inserted from the external jugular vein into the right ventricle (RV), so that the top of the catheter attained the RV interior (diaphragmatic) wall. The proximal and distal pairs of electrodes were used for recording and pacing the right atrium (RA) and RV. ECG channels were filtered between 0.5-250 Hz and intracardiac electrograms between 40-400 Hz. All the data were displayed on an oscilloscope and simultaneously printed with thermal printer (Fukuda Denshi MCS 5000, Fukuda Denshi Corporation, Japan).
Electrophysiological Study Protocol Standard clinical EPS protocol was employed to determine the electrophysiological parameters. Sinus node function was evaluated by measuring sinus node recovery time (SNRT) at 5 different pacing drive circles (100-60 ms). The rate-corrected SNRT (CSNRT) was defined as the sinus cycle subtracted from SNRT. Atrioventricular (AV) conduction properties with AV node (AVN)-Wenckebach cycle length (AV-WPCL) were assessed with rapid RA pacing at rates from 600 up to 1,000 beats/min. Programmed RA stimulation was performed to determine AVN and RA effective refractory period (ERP). Single, double and triple extra stimulation techniques (down to a minimum coupling interval 10 ms) were used to induce atrial arrhythmias. RV burst pacing was performed at rate 600-1,000 beats/min to assess the retrograde ventricular-atrial (VA) conduction, through measuring the ventricular atrium Wenckebach cycle length (VA-WPCL). After the RV-ERP was determined using the extra RV stimulation method, double and triple extra-stimulations were then employed to induce ventricular tachycardia (VT). If ventricular arrhythmia was induced, the test was repeated several times to ensure the reproducibility. When VT or AF was repeatedly provoked at least twice, we considered that the induction test was positive. After EPS, the mice were killed, their heart weight was measured and the ratio of heart weight (HW, mg) over body weight (BW, g) was calculated. The investigation conformed to the guiding principles of Kyoto University Graduate School of Medicine with the regard to animal care and the American Heart Association on research animal use. Statistical Analysis All statistical analyses were performed with SPSS software. Values are presented as the mean ± standard deviation. The difference between the 3 groups was tested using a two-way ANOVA or chi-square distribution test where appropriate. An ANOVA test was used in comparisons of echocardiographic and EPS data among 3 groups. A value of p<0.05 was considered statistically significant. (Table 2, Fig 1) Before the TAC operation, the LV wall thickness measured using echocardiography (Fig 1A, base) and there was no significantly difference between the 3 groups, but it progressively increased in TAC mice by 2 and 4 weeks after operation ( Table 2 , Fig 1A) . Panel B of Fig 1 summarizes the thickness of LV posterior wall in diastole (LVPWD) before the operation, and 2 and 4 weeks after the TAC operation. In the TAC group, 4 weeks after the operation, the LVPW increased to 1.07±0.27 mm (p<0.01 vs control group, 0.69±0.06 mm). The HW/BW ratio in the TAC group was 6.6±0.7 and was significantly larger than that in the control group (p<0.01 vs control group, 4.6±0.3) ( Table 2 , Fig 1C) .
Results

Effects of ARB on TAC-Induced Cardiac Hypertrophy
The continuous administration of candesartan (0.1 mg· kg -1 ·day -1 ) partially inhibited the increase in the LV wall thickness. In candesartan, 4 weeks after the TAC operation, the LVPWD (0.92±0.09) and HW/BW ratio (5.8±0.3) were significantly smaller (p<0.05 and p<0.01, respectively) than those in TAC group (Table 2 and Fig 1) . Thus, the drug produced a partial regression of the TAC-induced LVH. (Table 3) In TAC group, 4 weeks after operation, heart rates decreased, and P-wave duration, PR interval, AV interval, ERP-AVN, SNRT, CSNRT, AV-WPCL and VA-WPCL were all prolonged (vs control group p<0.05 or p<0.01). However, the duration of RA and RV waves, ERP-RV and ERP-RA were not significantly changed. In contrast, in candesartan group, all abnormal electrophysiological parameters found in TAC group were restored to normal, except the P-wave duration, which was still longer than that of the control group (Table 3) .
Influence of Candesartan on Electrophysiological Parameters in Control Mice
Induction of Ventricular Arrhythmia
Fig 2 illustrates a typical example of non-sustained VT induced by programmed ventricular stimulation in a TAC group mouse. This type of VT was induced in 12 out of 16 mice in TAC group (75.0%, p<0.01 vs control group) and was spontaneously terminated. The QRS morphology resembled that of torsades de pointes (Fig 2) . The number of induced VT varied between 6 and 20 per mouse, and the average duration was 714±250 ms (320-1,240 ms). In candesartan group, VT was induced only in 2 out of 16 mice (12.5%, p<0.01 vs TAC group; but NS vs control group), and the average VT duration was significantly shorter than that of the TAC group (Table 4) . In contrast, no VT was induced in the control group. These results indicated that candesartan could reduce the occurrence of VT in mice with LVH induced by TAC operation.
Induction of AF
In TAC group, short duration of AF could be induced by programmed or burst RA pacing in 8 out of 16 mice (50%, p<0.01 vs TAC and control groups, Table 4 and Fig 3) . The duration of AF was brief and ranged between 200 and 420 ms. The RA electrocardiogram (Fig 3, RA) showed disorganized and irregular atrial activities similar to those observed during EPS in humans. In contrast, no AF was induced in candesartan group (Table 4) .
Discussion
The present study demonstrated that candesartan -given at a dose that did not decrease systemic blood pressureinhibited the LVH progression, normalized the abnormal electrophysiological parameters and reduced the vulnerability to AF and VT in the mouse TAC model. The progression and development of control by TAC procedure are known to be associated with increased myocardial ACE activity and AngII forming pathways. 27 In addition to the kidney, the myocardium itself can produce AngII in a paracrine and/or autocrine fashion. 28 Besides its blood pressure-raising effects, AngII is a potent growth-stimulating peptide and plays a crucial role in the development of LVH. [3] [4] [5] 17, 29 Therefore, in the TAC mouse model, the AngII-mediated pathway may be a critical determinant of LVH. Rials and his colleagues reported that long-term treatment with ACE inhibitors prevented or reversed LVH as well as associated structural and functional abnormalities in the reno-vascular hypertensive rabbit model. 4, 30 However, losartan could not completely regress LVH in the same animal model. 5 In addition to reducing the AngII production, an ACE inhibitor can influence a number of enzyme pathways. AngII has multiple effects, but only some of them are mediated by the AT1 receptor. Thus, the ACE inhibitor could reverse the LVH, but the ARB partially regressed in the reno-vascular hypertension model. 5 In the present study, we demonstrated that long-term treatment with candesartan partially attenuated the cardiac hypertrophy induced by TAC in mice. Moreover, the dosage of candesartan we employed did not affect the blood pressure, thereby suggesting that the drug inhibited the growthpromoting effects of AngII via AT1 receptors in both atrial and ventricular myocytes.
There is an increasing recognition that arrhythmogenic mechanisms in the presence of LVH involve both cellular and tissue remodeling. Cellular studies consistently revealed the prolongation of action potential duration and the increased tendency for afterdepolarization, both of which are arrhythmia-triggering factors. 31, 32 The focal cellular mechanism seems to be important for the initiation of arrhythmia in patients with cardiomyopathy, but changes in the myocardium, which involved intercellular coupling, scaring and fibrosis, also constitute a macroscopic arrhythmogenic substrate. Both electrophysiological and structural remodeling contributes to maintaining the arrhythmia in LVH. 13, 33 In our experimental model with TAC, we observed that chronic treatment with candesartan did normalize several electrophysiological parameters such as PR interval, ERP-AVN, SNRT, CSNRT AV-WPCL and VA-WPCL (Table 3 ). The TAC procedure also prolonged ERP-RV, and candesartan returned this value to the control level, although there was no statistical significance. Therefore, chronic treatment with candesartan did not only regress LVH, but normalized abnormal electrophysiological parameters (Figs 1 and 2 ).
Rials and colleagues confirmed that the effects of AT1 blockade on the regression of LVH could also reverse abnormal LV electrophysiology both in vivo and in vitro models, suggesting that ARB works antiarrhythmically by preventing the left ventricular remodeling. 4, 5 In preliminary experiments, we examined the histology of the mice hearts after sham, TAC, and TAC plus candesartan treatments. The chronic treatment with the ARB partially inhibited the development of interstitial fibrosis, though it did not reach the statistical significance (Yasuno S, unpublished data). These histological findings were consistent with LVH detected by echocardiographic results (Figs 1A and B) and direct measurement of heart/body weight ratio (Fig 1C) . A similar prevention of atrial structural remodeling was also reported in a rapid pacing canine model, and therefore the ARB may have improved electrophysiological parameters regarding sinoatrial and AV conductions in our experimental model too. 34 Nakashima and colleagues also demonstrated that candesartan could decrease the morbidity of AF by preventing atrial electrical remodeling in dogs, although their experimental model was different from ours. 35 More recently, using the same canine rapid pacing model, Kumagai and colleagues reported that chronic treatment of candesartan significantly reduced the mean duration of AF, and prevented the shortening of atrial ERP and the prolongation of intra-atrial conduction time. 34 They also inspected the histological change in canine atria and found that candesartan significantly decreased the percentage of interstitial fibrosis. In the present study, candesartan was shown to prevent the induction of AF in TAC-treated mice entirely (Fig 3 and Table 4 ). Taken together, these results may explain why ARBs attenuated the incidence rate of de novo AF in humans. [18] [19] [20] In conclusion, candesartan treatment remarkably suppressed the occurrence of both atrial and ventricular arrhythmias during EPS. This may be attributable to the normalization of cardiac structural and functional abnormalities through the inhibition of AT1 receptors. This is the first report that the ARB can reduce the arrhythmia morbidity in the mouse LVH model.
